Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

LifeStance Health (LFST) Shares Outstanding (Weighted Average): 2021-2024

Historic Shares Outstanding (Weighted Average) for LifeStance Health (LFST) over the last 4 years, with FY2024 value amounting to $379.1 million.

  • LifeStance Health's Shares Outstanding (Weighted Average) rose 318.13% to $379.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $379.1 million, marking a year-over-year increase of 318.13%. This contributed to the annual value of $379.1 million for FY2024, which is 318.13% up from last year.
  • Per LifeStance Health's latest filing, its Shares Outstanding (Weighted Average) stood at $379.1 million for FY2024, which was up 318.13% from $367.5 million recorded in FY2023.
  • In the past 5 years, LifeStance Health's Shares Outstanding (Weighted Average) registered a high of $379.1 million during FY2024, and its lowest value of $327523.0 during FY2021.
  • Over the past 4 years, LifeStance Health's median Shares Outstanding (Weighted Average) value was $361.4 million (recorded in 2022), while the average stood at $275.6 million.
  • In the last 5 years, LifeStance Health's Shares Outstanding (Weighted Average) surged by 10837421.4% in 2022 and then skyrocketed by 318.13% in 2024.
  • Annual analysis of 4 years shows LifeStance Health's Shares Outstanding (Weighted Average) stood at $327523.0 in 2021, then surged by 108374.21% to $355.3 million in 2022, then increased by 3.43% to $367.5 million in 2023, then rose by 3.18% to $379.1 million in 2024.
  • Its Shares Outstanding (Weighted Average) stands at $379.1 million for FY2024, versus $367.5 million for FY2023 and $355.3 million for FY2022.